CE Webinar: One baby to drug approval: Moving toward equity with human milk feeding in VLBW infants

Overview:

Explore the evolution of an exclusive human milk diet (EHMD) in Japan and its role in supporting very low birth weight (VLBW) infants. Join Professor Katsumi Mizuno and Dr. Melinda Elliott as they review the clinical rationale for EHMD, findings from the Mizuno study, and considerations for balancing growth, safety, and equitable access to human milk-based nutrition.

Objectives:

• Explain the clinical and nutritional challenges that led to the development of EHMD in Japan.
• Differentiate EHMD from conventional feeding strategies, including the roles of mother’s own milk,
  donor human milk, and human milk-derived fortifiers.
• Interpret the Mizuno study’s findings on weight-gain velocity, time to full enteral feeding, adverse
  events, and preliminary IGF-1 data.
• Apply the evidence to interdisciplinary decisions about standardized EHMD protocols and their
  equitable implementation across neonatal care settings.

Speakers:

Katsumi Mizuno, MD, PhD
The Showa University School of Medicine

Melinda Elliott, MD, FAAP

Chief Medical Officer, Prolacta Bioscience

Amanda Salley, MS, RD, CSP, LDN

Medical Science Liaison - Neonatal & Pediatric Nutrition, Prolacta Bioscience

Target Audience:

This 1-hour program is designed for the healthcare professional caring for premature infants.

Contact Hour: Provided by Kendra S. Schreiner RN18160 Cottonwood Rd., PMB 352 Sunriver, OR 503-467-661. An Independent Provider approved by the California Board of Registered Nursing. The activity number is 194682 and the Performance Indicators are: 2.1.1, 2.3.4, 7.2.1, 7.2.3. This program is approved for 1 nursing contact hour and 1 CPEU for dietitians.

Disclaimer: The experiences, opinions, and results shared in this video reflect those of the speaker and do not necessarily represent the views of Prolacta. Certain statements, including referenced studies, are based on data that have been submitted to or evaluated by the U.S. Food and Drug Administration (FDA); however, other statements reflect the speaker’s interpretations and have not been reviewed by the FDA.

Professor Mizuno received compensation from Prolacta for this presentation and provides additional services to the company.